| Journal Article |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| A real options perspective on R&D portfolio diversification |
0 |
0 |
0 |
24 |
4 |
8 |
11 |
162 |
| Buy Smart, Time Smart: Are Takeovers Driven by Growth Opportunities or Mispricing? |
0 |
0 |
0 |
22 |
0 |
2 |
2 |
69 |
| Correction to: Dodging bullets: The heterogeneous effect of political violence on greenfield FDI |
0 |
0 |
0 |
16 |
3 |
5 |
6 |
124 |
| Corrigendum to "Tariffs, licensing and market structure": [European Economic Review 50, (2006), 1699-1707)] |
0 |
0 |
0 |
28 |
0 |
2 |
2 |
84 |
| Defensive Disclosure of Patentable Inventions under Antitrust Enforcement |
0 |
0 |
0 |
2 |
2 |
7 |
9 |
27 |
| Dodging bullets: The heterogeneous effect of political violence on greenfield FDI |
0 |
2 |
2 |
38 |
0 |
8 |
17 |
199 |
| Domestic plant productivity and incremental spillovers from foreign direct investment |
0 |
0 |
1 |
48 |
2 |
6 |
9 |
190 |
| Employee layoff under different modes of restructuring: exit, downsizing or relocation |
0 |
0 |
1 |
26 |
1 |
4 |
8 |
138 |
| Evaluating pharmaceutical R&D under technical and economic uncertainty |
0 |
0 |
0 |
68 |
0 |
7 |
10 |
203 |
| Heterogeneous Firms and Asymmetric Product Differentiation |
0 |
0 |
0 |
16 |
0 |
4 |
9 |
59 |
| How Does Regulation Impact Strategic Repositioning by Firms Across Submarkets? Evidence from the Indian Pharmaceutical Industry |
1 |
2 |
4 |
7 |
4 |
9 |
12 |
30 |
| How to finance your investment opportunity internally: A note |
0 |
0 |
0 |
1 |
0 |
1 |
1 |
9 |
| How to maximize domestic benefits from foreign investments: the effect of irreversibility and uncertainty |
0 |
0 |
0 |
76 |
1 |
6 |
9 |
201 |
| INTERNATIONAL RELOCATION OF PRODUCTION: WHERE DO FIRMS GO? |
0 |
0 |
2 |
123 |
2 |
7 |
11 |
436 |
| Imitation, patent protection, and welfare |
0 |
0 |
0 |
60 |
0 |
6 |
9 |
228 |
| International relocation: firm and industry determinants |
0 |
0 |
0 |
282 |
2 |
7 |
11 |
602 |
| Learning dynamics in research alliances: A panel data analysis |
0 |
0 |
0 |
32 |
4 |
8 |
13 |
236 |
| Learning from foreign investment by rival firms: Theory and evidence |
0 |
0 |
0 |
35 |
0 |
5 |
9 |
106 |
| Market entry, phased rollout or abandonment? A real option approach |
0 |
0 |
1 |
55 |
0 |
2 |
7 |
187 |
| OPTIMAL PRICING AND QUALITY CHOICE WHEN INVESTMENT IN QUALITY IS IRREVERSIBLE |
0 |
0 |
0 |
39 |
0 |
3 |
11 |
150 |
| On the Stability of Research Joint Ventures: Implications for Collusion |
0 |
0 |
0 |
0 |
0 |
4 |
7 |
48 |
| On the relation between multimarket contact and service quality: Mutual forbearance or network coordination? |
0 |
0 |
0 |
8 |
2 |
12 |
13 |
62 |
| Optionsmanagement in F&E: Eine Fallstudie |
0 |
0 |
0 |
0 |
0 |
2 |
2 |
2 |
| Price asymmetries and the path dependence of market power: Evidence from the U.S. airline industry |
0 |
0 |
3 |
8 |
1 |
7 |
11 |
28 |
| Price or quantity setting under uncertain demand and capacity constraints: An examination of the profits |
0 |
0 |
0 |
16 |
0 |
1 |
1 |
58 |
| Privatization of real options |
0 |
0 |
0 |
25 |
0 |
4 |
9 |
117 |
| R&D collaboration, social coordination, and standardization: evidence from the Chinese automotive industry |
0 |
0 |
0 |
4 |
2 |
9 |
12 |
26 |
| Real options and institutions |
0 |
0 |
1 |
45 |
2 |
6 |
12 |
193 |
| Real options with ex-post division of the surplus |
0 |
0 |
0 |
11 |
3 |
7 |
11 |
69 |
| Strategic diversification and capacity utilization |
0 |
0 |
0 |
13 |
2 |
8 |
10 |
82 |
| Tariffs, licensing and market structure |
0 |
0 |
1 |
75 |
1 |
3 |
6 |
213 |
| Taxes and stimuli of investment under uncertainty |
0 |
1 |
2 |
82 |
0 |
8 |
13 |
194 |
| The Hazard Rate of Foreign Direct Investment: A Structural Estimation of a Real‐option Model* |
0 |
0 |
1 |
62 |
0 |
3 |
7 |
247 |
| The V-shaped value evolution of R&D projects |
0 |
0 |
1 |
33 |
1 |
4 |
7 |
186 |
| The choice and timing of foreign direct investment under uncertainty |
0 |
0 |
0 |
64 |
0 |
7 |
11 |
163 |
| The moderating role of absorptive capacity and the differential effects of acquisitions and alliances on Big Pharma firms' innovation performance |
0 |
1 |
2 |
2 |
1 |
5 |
10 |
24 |
| The option value of advanced R & D |
0 |
0 |
0 |
83 |
2 |
4 |
8 |
248 |
| Trademark or patent? The effects of market concentration, customer type and venture capital financing on start-ups’ initial IP applications |
1 |
1 |
1 |
8 |
1 |
10 |
13 |
56 |
| Unionization structure, licensing and innovation |
0 |
0 |
1 |
40 |
5 |
16 |
18 |
160 |
| When political instability devaluates home-host ties |
1 |
1 |
1 |
17 |
2 |
8 |
12 |
119 |
| Total Journal Articles |
3 |
8 |
25 |
1,594 |
50 |
235 |
369 |
5,735 |
LogEc is hosted by the
Örebro University School of Business.